Elekta (OTCMKTS:EKTAY) Downgraded to “Strong Sell” Rating by Zacks Research

Elekta (OTCMKTS:EKTAY) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Elekta Trading Down 2.2%

Shares of Elekta stock opened at $5.63 on Tuesday. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -35.19 and a beta of 1.00. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.56. Elekta has a 12-month low of $4.35 and a 12-month high of $6.93. The firm’s 50-day moving average price is $5.99 and its two-hundred day moving average price is $6.02.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 10.67%. The firm had revenue of $521.00 million for the quarter. On average, analysts forecast that Elekta will post 0.43 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.